MSLN Antibody, Biotin conjugated

1. Elevated plasma MSLN level is related with epithelial ovarian cancer. PMID:30319054
2. We have demonstrated that a rising serum mesothelin is a sensitive marker of progression in the follow up of patients with MPM. PMID:29454314
3. we engineered variants of the fibronectin type III domain (Fn3) non-antibody protein scaffold to bind to mesothelin with high affinity, using directed evolution and yeast surface display PMID:29738555
4. Our goal was to stimulate antitumor immunity by combining SS1P or LMB-100 with anti-CTLA-4. We constructed a BALB/c breast cancer cell line expressing human mesothelin (66C14-M), which was implanted in one or two locations. SS1P or LMB-100 was injected directly into established tumors and anti-CTLA-4 administered i.p. In mice with two tumors, one tumor was injected with immunotoxin and the other was not. PMID:28674083
5. Mesothelin-targeted immunotoxin RG7787 increases pancreatic cancer cell sensitivity to taxane-mediated killing by increasing taxane-mediated microtubule stability and priming cells for apoptosis by decreasing levels of the pro-survival factor Mcl-1. PMID:27999204
6. RG7787 plus nab-paclitaxel is very active against primary human mesothelioma cells in vitro as well as in vivo, with serum mesothelin levels correlating with tumor response. These results indicate that this combination could be useful for treating patients with mesothelioma PMID:27635089
7. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. PMID:28929447
8. Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.( PMID:28287406
9. MiR-21-5p is suggested as novel regulator of MSLN with a possible functional role in cellular growth. PMID:28125734
10. we report herein that high tumor mesothelin expression predicts a shorter PFS and OS in EOC patients and demonstrates that serum mesothelin predicts local tumor mesothelin expression. PMID:28160193
11. We provide new evidence for the role of MSLN in EMT regulation, tumorigenesis and metastasis. Knockdown of MSLN led to mesenchymal to epithelial transition and less aggressive behavior of lung carcinoma and mesothelioma cells. PMID:28288645
12. MSLN expression increases cell migration and invasion in vitro. PMID:27422997
13. SMRP but not FBLN3 has a role in pleural effusions in in malignant pleural mesothelioma PMID:28314308
14. High mesothelin expression is associated with malignant pleural mesothelioma. PMID:27646775
15. Calretinin, D2-40 and mesothelin are aberrantly expressed in a proportion of CRC cases. PMID:27062033
16. Our results showed that IMP3 immunostaining has a higher sensitivity and specificity than mesothelin for the diagnosis of pancreatic ductal adenocarcinoma. IMP3 and mesothelin may be useful markers in distinguishing neoplastic from reactive lesions of the pancreas in instances where this is impossible by morphology alone in surgical pathology practice. PMID:26874572
17. Results indicate a specific mesothelin-driven tumor uptake of targeted 89zirconium-labeled antibody which visualizes mesothelin expressing pancreatic cancer in real time. PMID:26536664
18. Data indicate that triple-negative breast cancer (TNBC) showed the highest amplification rate (42%) in the basal-like 1 subtype. PMID:26172299
19. There was a trend toward elevation of SMRP values in healthy individuals exposed to asbestos compared to those without exposure. Within asbestosis cases, those with higher profusion scores had higher SMRP values than those with lower profusion scores. PMID:26188910
20. High mesothelin expression was strongly associated with mutant KRAS/wild-type EGFR and poor prognosis in advanced lung cancer. PMID:26028668
21. findings replicate association between rs1057147 and soluble mesothelin related peptide(SMRP)levels; SMRP performance as diagnostic biomarker for malignant pleural mesothelioma improved by considering genotype rs1057147; this polymorphism most likely affects a binding site for miR-611 PMID:25436799
22. Expression of mesothelin was observed in 42.3% of patients with triple negative breast cancer. PMID:25776500
23. Patients with mesothelin-positive triple negative breast carcinomas (TNBC) were older than patients with mesothelin-negative TNBC, developed more distant metastases with a shorter interval, and had significantly lower overall and disease-free survival. PMID:25506917
24. Delivery of mesothelin-targeted CAR T cells eradicates tumors in mice with pleural malignancies. PMID:25378643
25. Pleural fluid mesothelin may serve as a marker for pleural malignant mesothelioma. PMID:25505814
26. Patients with colon cancer had significantly higher mesothelin serum levels than the control groups. PMID:25477701
27. Mesothelin expression is associated with poor outcomes in breast cancer.Mesothelin is a prognostic breast tumor marker whose expression is highly enriched in triple negative breast cancer tumors. PMID:25193277
28. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. PMID:25227779
29. Both the serum CA125(meso) level and the ratio of the serum CA125(mesothelin) to CA125 levels (CA125(mesothelin) /CA125) were significantly higher in patients with EOC. PMID:25197000
30. Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel for pancreatic cancer. PMID:24308545
31. MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere formation in MSLN-overexpressing Mero-14 cells. PMID:24465798
32. Being negative/focally positive for mesothelin expression was associated with longer postoperative survival than positive expression in patients with cholangiocellular carcinoma. Mesothelin positivity was a predictor of short postoperative survival. PMID:23701154
33. Our findings suggest that MLSN can be used as a marker of neoplastic transformation of epithelial cells in pancreatic mucinous cysts. PMID:25125620
34. MSLN expression in patients with early-stage lung adenocarcinoma is associated with increased risk of recurrence and reduced overall survival. PMID:24334761
35. These data provides evidence for the use of mesothelin as an immunogen for tumour-specific T cell response. PMID:24520352
36. Mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. PMID:23512344
37. In the gastric cancer tissues, C-ERC/mesothelin expression was associated with lymphatic invasion. N-ERC/mesothelin was secreted into the supernatants of gastric cancer cell lines, but does not appear to be a useful serum marker of gastric cancer. PMID:24146039
38. Use of S100P and mesothelin in cytologically borderline cases can increase the diagnostic accuracy for pancreatic adenocarcinoma. PMID:21538952
39. Data indicate that biochemical markers significantly associated with mesothelioma were hyaluronan, N-ERC/mesothelin and syndecan-1. PMID:23991032
40. PE-SMRP adds some clinical information in the work-up of patients with a PE of unknown origin. PMID:23873013
41. Mesothelin expression was identified in 34% of patients with triple receptor negative breast cancer. PMID:23810431
42. addition of YKL-40 may improve the specificity of mesothelin measurements alone for detecting patients with multiple myeloma PMID:24324091
43. These data suggest that in difficult diagnostic cases both PAX2 and mesothelin immunohistochemical study may be useful in discriminating between PMRCC and primary pancreatic carcinoma. PMID:24344503
44. SMRP could improve CYFRA 21-1 antigen and carcinoembryonic antigen (CEA) accuracy in the differential diagnosis of malignant pleural mesothelioma. PMID:23532816
45. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. PMID:23694968
46. Mesothelin, megakaryocyte potentiating factor and osteopontin are expressed in malignant mesothelioma [review] PMID:22835614
47. MSLN overexpression promoted the invasive potential of MCF-7 cells through ERK1/2-dependent upregulation of MMP-9; this association may have contributed to metastasis of MCF-7 cells in vivo. PMID:23321167
48. Data indicate that binding of mesothelin to CA125 does not alter the measurement of mesothelin for the detection of malignant mesothelioma (MM). PMID:23357461
49. The mesothelin expression promotes resistance to certain chemotherapy drugs such as TNF-alpha, paclitaxel, and a combination of platinum and cyclophosphamide. PMID:22721387
50. SMRP was lower in healthy subjects than in subjects with malignant tumors, asbestos-related pleural lesions, and other benign diseases PMID:23277285

Show More

Hide All

HGNC: 7371

UNIGENE: Hs.408488

KEGG: hsa:10232

STRING: 9606.ENSP00000372313

OMIM: 601051